v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 749,813 $ 75,532
General and administrative 1,533,926 1,643,163
Total operating expenses 2,283,739 1,718,695
Loss from operations (2,283,739) (1,718,695)
Interest income, net and other 59,111 9,162
Loss from continuing operations (2,224,628) (1,709,533)
Net loss (2,224,628) (1,709,533)
Loss from continuing operation, Total (2,224,628) (1,709,533)
Loss from continuing operations attributable to common stockholders $ (2,224,628) $ (1,709,533)
Net loss per share attributable to common stockholders - basic $ (4.18) $ (240.07)
Net loss per share attributable to common stockholders - diluted (4.18) (240.07)
Total net loss per share - basic (4.18) (240.07)
Total net loss per share - diluted $ (4.18) $ (240.07)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic 531,968 7,121
Weighted-average number of common shares used in net loss per share attributable to common stockholders - diluted 531,968 7,121